ReviewVirology2015
Molecular biology of hepatitis B virus infection.
Review in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 467 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
467 citing papers in PubMed, 1 synthesis or guideline pooled it, 844 citations in OpenAlex.
- HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.Hepatology communications · 2022Trial
- Natural products targeting hepatitis B virus X protein and HBx-associated pathways in HBV-related hepatocellular carcinoma: mechanisms and therapeutic potential.Pharmaceutical biology · 2026Review
- Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach.Virus research · 2026Review
- Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).Journal of virology · 2026Article
- Pilot Evaluation of Simplified HBV DNA Extraction-LAMP Workflows for Hepatitis B Molecular Testing in Resource-Limited Settings.Diagnostics (Basel, Switzerland) · 2026Article
- Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.Journal of virology · 2026Article
- Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV.AIDS (London, England) · 2026Review
- Promotion of hepatitis B virus infection by extracellular apolipoprotein E.Journal of virology · 2026Article
- Article
- Review
- Combined C-terminal truncation and point mutations in HBx in genotype D1 HBV-associated hepatocellular carcinoma.Infectious agents and cancer · 2026Article
- Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus.Science advances · 2026Article
- Free-Energy Landscapes of HBV Hexamer Closure Reveal Key Structural Features of the Transition.Journal of chemical theory and computation · 2026Article
- Hepatitis B virus functional cure in persons with HIV: what are the predictors and which novel markers are useful?Current opinion in HIV and AIDS · 2026Review
- mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.Biomolecules · 2026Review
- Detection and characterization of Hepatitis B virus double-stranded linear DNA-derived covalently closed circular DNA in chronic hepatitis B patients.PLoS pathogens · 2026Article
- Vaccination Coverage and Awareness on Hepatitis B Virus Among High School, College, and University Students of Rajshahi Division of Bangladesh: A Cross-Sectional Study.Health science reports · 2026Article
- Implications of occult hepatitis B infection for blood donor management: a five-year evaluation from Western Saudi Arabia.BMC infectious diseases · 2026Article
- TCMToxDB: a comprehensive database for the toxicological analysis of traditional Chinese medicines.Database : the journal of biological databases and curation · 2026Article
407 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human hepatitis B virus (HBV) is the prototype of a family of small DNA viruses that productively infect hepatocytes, the major cell of the liver, and replicate by reverse transcription of a terminally redundant viral RNA, the pregenome. Upon infection, the circular, partially double-stranded virion DNA is converted in the nucleus to a covalently closed circular DNA (cccDNA) that assembles into a minichromosome, the template for viral mRNA synthesis. Infection of hepatocytes is non-cytopathic. Infection of the liver may be either transient (<6 months) or chronic and lifelong, depending on the ability of the host immune response to clear the infection. Chronic infections can cause immune-mediated liver damage progressing to cirrhosis and hepatocellular carcinoma (HCC). The mechanisms of carcinogenesis are unclear. Antiviral therapies with nucleoside analog inhibitors of viral DNA synthesis delay sequelae, but cannot cure HBV infections due to the persistence of cccDNA in hepatocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.